In prostate cancer, fatostatin suppresses cell proliferation and colony formation in both androgen-responsive or -insensitive cancer cells and causes G2/M cell cycle arrest and cell death, which is mediated by the blockade of the SREBP-regulated metabolic pathway and AR signaling network (136). Here, AR is linked to prostate carcinoma.